Audentes Therapeutics, Inc. (NasdaqGM:BOLD) will look for acquisitions and investments. We will continue to require additional financing to advance our current product candidates through clinical development, to develop, acquire or in-license other potential product candidates and to fund operations for the foreseeable future. We will continue to seek funds through equity or debt financing, collaborative or other arrangements with corporate sources, or through other sources of financing.